The outcome for children with high-grade gliomas (HGG) remains dismal, with a twoyear survival rate of only 10-30%. Diffuse intrinsic pontine glioma (DIPG) comprise a subset of HGG that arise in brainstem almost exclusively in children. Genome-wide analyses of copy number imbalances previously showed that platelet derived growth factor receptor alpha (PDGFRA) is the most frequent target of focal amplification in pediatric HGGs, including DIPGs. To determine whether PDGFRA is also targeted by more subtle mutations missed by copy number analysis, we sequenced all PDGFRA coding exons from a cohort of pediatric HGGs. Somatic activating mutations were identified in 14.4% (13/90) of non-brainstem pediatric HGGs and 4.7% (2/43) of DIPGs, including missense mutations and in-frame deletions and insertions not previously described. 40% of tumors with mutation showed concurrent amplification, while 60% carried heterozygous mutations. Six different mutations impacting different domains all resulted in ligand-independent receptor activation that was blocked by small molecule inhibitors of PDGFR. Expression of mutants in p53-null primary mouse astrocytes conferred a proliferative advantage in vitro, and generated HGGs in vivo with complete penetrance when implanted into brain. The gene expression signatures of these murine HGGs reflected the spectrum of human diffuse HGGs. PDGFRA intragenic deletion of exons 8 and 9 were previously shown in adult HGG, but were not detected in 83 nonbrainstem pediatric HGG and 57 DIPGs. Thus, a distinct spectrum of mutations confers constitutive receptor activation and oncogenic activity to PDGFRα in childhood HGG.
Introduction
Pediatric high-grade gliomas (HGGs) comprise 15-20% of all childhood tumors of the central nervous system (1) . Despite aggressive therapy, prognosis for pediatric HGG remains very poor, with a two-year survival rate of less than 20% (2) . A subset of HGGs arise in the brainstem as diffuse intrinsic pontine glioma (DIPG), a disease that occurs almost exclusively in children, and has a two-year survival rate of less than 10% (3) .
Although the histopathologies of pediatric and adult HGGs can be similar, genome-wide studies have shown significant differences in the frequencies of specific copy number alterations (CNAs) as well as both similarities and differences in the gene expression signatures of HGGs in these two age groups (4) (5) (6) (7) (8) (9) (10) (11) (12) . Somatic mutations in histone H3 occur in 78% of DIPGs and 36% of non-brainstem pediatric glioblastomas, but occurred only rarely in young adults with glioblastoma, and not in older adult glioblastoma patients (11, 12) . Thus, distinct molecular mechanisms drive gliomagenesis at different ages.
Platelet derived growth factor receptor alpha (PDGFRA) is the most frequent target of focal amplification in pediatric HGGs arising within and outside the brainstem (4) (5) (6) (7) 10) , and somatic mutations of PDGFRA have been recently reported in pediatric HGGs (6, 12) . In contrast, epidermal growth factor receptor (EGFR) is the predominant receptor tyrosine kinase targeted by both amplification and mutation in adult glioblastoma (13, 14) . Pediatric HGGs with genomic amplification of PDGFRA showed concomitant increases in PDGFRA mRNA by gene expression profiling. Furthermore, PDGFRĮ overexpression without genomic amplification is commonly found in pediatric HGGs, and amplification of the genes encoding PDGF ligands, or overexpression with and Research.
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PDGF and its receptors are involved in many cellular processes such as migration, survival and proliferation, and they are critical during developmental processes (15) .
Ligand binding induces receptor dimerization and results in phosphorylation of the receptor at multiple tyrosine residues. Activated PDGFRs transduce signals through multiple downstream pathways, including the PI3K/Akt, RAS/MAP kinase, Src kinase family and PLC/PKC pathways, which have all been implicated in tumorigenesis (15, 16) .
Abnormally activated PDGFRĮ signaling driven by viral expression of PDGFB ligand is sufficient to induce glioma formation in vivo, indicating that activation of PDGFR pathways is potentially an early event in tumorigenesis (17) (18) (19) . Furthermore, simultaneous overexpression of PDGFB and loss of TP53 induced murine HGG with increased incidence and shorter latency indicating cooperativity between these pathways (20, 21) . However, these studies focused on autocrine and paracrine activation of PDGFR signaling pathways by PDGFB ligand overexpression.
Here we report that pediatric HGGs, including DIPGs, carry novel somatic activating mutations of PDGFRA that are constitutively active, tumorigenic, and sensitive to small molecule inhibitors.
Research.
Author Manuscript Published OnlineFirst on August 22, 2013; DOI: 10.1158/0008-5472. CAN-13-1491 In vitro analyses of overexpression of wild-type and mutant PDGFRA Wild type and mutated PDGFRA open reading frames were cloned into the MSCV-IRES-GFP (MIG) retroviral vector and used to generate retrovirus (24) . Cortical astrocyte cultures were established from two-day old mice (GFAP-cre;Trp53 loxP/loxP ) as described previously (25) . At passage one, p53-null astrocytes were transduced with retroviruses expressing wild type PDGFRĮ, PDGFRĮ mutants or empty vector, and in vitro and tumorigenesis experiments were performed before passage six. For proliferation assays, 5.5 x 10 3 cells per well were plated on 96-well plates in triplicate.
Cells were grown in DMEM/F-12 supplemented with 10% FBS and 20 ng/mL mouse EGF (Millipore), but without exogenous addition of the PDGF ligand. Proliferation was measured using XTT assay (Roche) at 24 hour intervals over a four day period, without replacing the growth medium. For inhibitor studies, cells were allowed to attach for 4 hours after seeding, then 225 nM (100 ng/mL) Crenolanib (AROG Pharmaceuticals), 50 nM Dasatinib (LC Laboratories) or vehicle (0.1% DMSO) were added to the cells in a single dose, and growth was assayed by XTT as above. Data were normalized to the cell number measured at time zero of the experiment, which was acquired within the first 8 hours from cell seeding (4 hours for cell attachment and 4 hours for development of XTT). For cell cycle analyses, 2 x 10 6 cells were seeded per 10 cm dish and the next day cells were treated with 225 nM (100 ng/mL) crenolanib (AROG Pharmaceuticals), 50 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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Tumorigenesis studies
Mouse experiments were approved by the Institutional Animal Care and Use Committee and are in compliance with national and institutional guidelines. 2 x 10 6 transduced astrocytes were implanted intracranially into athymic nude mice for tumorigenesis studies as previously described (25) . On the manifestation of brain tumor symptoms, mice were anesthetized and perfused with PBS. GFP-labeled tumors were dissected using a fluorescent dissecting microscope. For each tumor, a portion was snap-frozen for protein analyses and RNA extraction, and the remainder was fixed in 4% paraformaldehyde in PBS at 4°C overnight, then processed, embedded in paraffin, and cut into 5 μm sections. Hematoxylin and eosin stained sections from all collected tumors were evaluated by a clinical neuropathologist (DWE) and graded according to WHO criteria (26) . Immunohistochemistry was performed with microwave antigen retrieval in a citrate solution using the following primary antibodies from Cell Signaling: PDGFRĮ (#5241), phospho-Akt S473 (#9271) and phospho-4E-BP1 Thr37/46 (#2855). Anti-rabbit biotinylated secondary antibodies were used in conjunction with horseradish peroxidase-conjugated streptavidin (Elite ABC, Vector Labs). Staining was developed with NovaRED substrate (Vector Labs) and the sections were counterstained with hematoxylin (Vector Labs).
Western blot analysis
Author Manuscript Published OnlineFirst on August 22, 2013; DOI: 10.1158/0008-5472. CAN-13-1491 Protein lysates were prepared in ice-cold RIPA buffer (150mM NaCl; 50mM Tris-HCl, 
Gene expression microarray analysis
Total RNA was extracted from frozen tumor tissue dissected from mice with wild-type PDGFRĮ, PDGFRĮ mutants and from parental p53-null mouse primary astrocytes. In addition, RNA was isolated from high-grade astrocytomas generated by implantation of EGFRvIII expressing p53-null PMAs as previously described (25) . Gene expression profiles were generated using the Affymetrix Mouse Genome 430 Perfect Match Peg Arrays. Gene expression profiles were generated using the Affymetrix Mouse Genome 430 Perfect Match Peg Arrays in two batches. Three common samples run in both sets were used for batch correction with the program ComBat (27) . Unsupervised hierarchical clustering analysis was carried out with the merged data using the 1000 most variable probe sets selected based on median absolute deviation (MAD) score.
Single-sample gene set enrichment analysis (GSEA) was performed as described previously (28, 29) . Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on August 22, 2013; DOI: 10.1158/0008-5472.CAN- previously published work (30, 31) . Data is deposited at www.ncbi.nlm.nih.gov/geo/, accession GSE46190.
Statistical Analysis
There was no apparent association between histological tumor type and the presence of PDGFRA mutation in pediatric HGG as assessed by exact chi-square test for independence (p=0.2562). A Kruskal-Wallis test showed that the presence of PDGFRA mutations was not significantly associated with age at diagnosis (p=0.068). Statistical significance of the associations of murine tumors driven by different PDFGRA mutations with histology, gene expression clusters, human HGGs gene expression signatures and neural cell type specific subgroups was assessed by exact chi-square test for independence. Student's two-tailed t-test p-values were calculated for cell cycle analysis to assess response to crenolanib and dasatinib versus untreated controls.
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Results

PDGFRA is frequently mutated in pediatric HGGs
Sequencing of all coding exons of PDGFRA in genomic DNA from 90 pediatric HGGs outside the brainstem, and 43 DIPGs identified 15 cases with mutated PDGFRA (Fig. 1 and Table S1 ). All mutations were confirmed by independent PCR reactions and were validated as somatic, found only in the tumor and not matching germline DNA when normal sample was available (Table S1 ). Mutations were identified in the extracellular, transmembrane and intracellular kinase domains and included missense mutations, inframe insertions or deletions ( Fig.1 ). Analysis of cDNA showed that one of the somatic point mutations, N468S, generated a new splice site that removed 13 amino acids (E10del2) ( Fig.S1A and Table S1 ). 60% (9/15) of the mutations were present as heterozygous alleles, and 40% (6/15) of mutations were also amplified. SNP array analyses previously showed copy number imbalances for the majority of the samples, demonstrating sufficient tumor purity to detect clonal alterations (4, 5) . Importantly, all mutations reported here were readily detected by Sanger sequencing, indicating clonal expansion of the population containing the mutation, particularly in the cases in which PDGFRA was not amplified. There was no association between the presence of PDGFRA mutation and histopathological features (p=0.26). Three mutations were found in anaplastic astrocytomas (3/24), one in an anaplastic oligodendroglioma (1/6), and the remaining mutations in grade IV glioblastomas, including two DIPGs (11/102) (Table S1 and S2). Both mutations in the kinase domain, N659K and D842V were previously reported in gastrointestinal stromal tumors but not in gliomas (32, 33 Y288C and C290R), three in-frame insertions (C450ins, A491ins and V544ins) and three in-frame deletions (E7del, E10del and E10del2) (Table S1) not found in previous studies of a large collection of pediatric HGGs or adult HGGs (6, 12, 23, 34) . Three of the identified mutations (E7del, E10del2 and N659K) were recurrent, each of them found in two different HGG cases.
We also evaluated whether activating PDGFRA mutations previously shown in adult HGG occur frequently in pediatric HGG. 40% of adult glioblastomas with PDGFRA amplification harbor an in-frame deletion of 243 base pairs in exons 8 and 9 of the extracellular portion of the receptor (PDGFRA ǻ8, 9 ) that renders the receptor constitutively active (23, 35) . A gene fusion between PDGFRA and KDR (VEGFR2), which rendered the receptor constitutively active and tumorigenic in vivo, has been reported in one out of 215 cases of adult glioblastoma. We used RT-PCR to screen for these alterations that would have been missed by exonic sequencing. We found one case of KDR-PDGFRA in 83 non-brainstem pediatric HGGs analyzed ( Fig. S1B ). There were no examples of the PDGFRA ǻ8, 9 deletion in 83 non-brainstem pediatric HGG, and 57 DIPG screened by RT-PCR ( Fig. S1C ). Thus, a different spectrum of intragenic mutations target PDGFRA in HGGs from different age groups.
PDGFRĮ mutants are constitutively active
To better understand the consequence of PDGFRĮ mutation in pediatric gliomagenesis, retroviral constructs expressing wild-type PDGFRĮ or six selected PDGFRĮ mutants that affect different regions of the receptor were generated for functional studies. p53- (16, (36) (37) (38) . Different levels of receptor phosphorylation were observed depending on the specific mutation, with the E10del2 exhibiting the lowest receptor activation. All mutants were expressed to similar levels as shown by total PDGFRĮ ( Fig. 2A, left) . In contrast, overexpression of wild-type PDGFRĮ did not lead to receptor activation in the ligand-free condition.
However, treatment of these cells with PDGF-AA, triggered wild-type PDGFRĮ phosphorylation to levels similar to or greater than the mutant receptors ( Fig.2A, right) . by the mutated receptor. Activation of MAPK signaling, detected by phosphorylation of p44/42 MAPK was not increased by mutant PDGFRĮ in the absence of ligand. Ligand stimulation further increased phosphorylation levels of PI3K pathway components but had only modest effect on the MAPK pathway activation ( Fig.2A and Fig.S2 ).
Expression of PDGFRĮ mutants as well as wild-type receptor added a significant proliferative advantage in comparison with empty vector control cells as determined by XTT assays (Fig.2B) .
PDGFRĮ signaling is abrogated by inhibitors
To analyze whether wild-type and PDGFRĮ mutants have differential responses to small molecule inhibitors, two distinct compounds were selected. Dasatinib (BMS-354825) is a potent, multi-tyrosine kinase inhibitor that exerts broad antiproliferative activity by targeting PDGFRĮ, PDGFRȕ, ABL, SRC family kinases, KIT and several other tyrosine kinases (39, 40) . In contrast, crenolanib (CP-868,596) is a relatively specific inhibitor of PDGFRĮ and PDGFRȕ, that is more than 100 fold more selective for PDGFRs versus a variety of other kinases (e.g. KIT, VEGFR-2, TIE-2, FGFR-2, EGFR, ERBB2, and SRC) (41, 42) . Both drugs have been shown to inhibit PDGFR kinase activity by competing with ATP. To compare wild-type and mutant PDGFRĮ signaling alterations in response to these inhibitors, cells were serum starved overnight, then treated with crenolanib or dasatinib for 3 hours before adding PDGF-AA ligand. As previously reported, the D842V mutant was resistant to dasatinib treatment, however it was effectively inhibited by crenolanib (42) . Both inhibitors significantly blocked activation of wild type PDGFRĮ and all other mutants analyzed as shown by decreased Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on August 22, 2013; DOI: 10.1158/0008-5472. CAN-13-1491 phosphorylation of the receptor at Tyr-572/574, Tyr-742, Tyr-720, and Tyr-754 ( Fig.3A) .
Furthermore, downstream signaling activation was significantly diminished, including decreased phosphorylation of PI3K and MAPK pathway effectors ( Fig.3A and Fig.S3A ).
D842V and V544ins were the only two mutants that induced a substantial increase in SHP2 phosphorylation (Fig S2) , and the only two mutants for which crenolanib induced a substantial decrease in phospho-SHP2 ( Fig S3A) .
The effect of each inhibitor on cell proliferation was examined by XTT assay (Fig.3B and Fig. S3B ), using a concentration greater than the IC90 determined to block receptor phosphorylation ( Fig. S4 ). Crenolanib selectively inhibited proliferation of PDGFRĮ expressing cells, both wild-type and all analyzed mutants, while it did not affect proliferation of the empty vector control cells ( Fig. 3B and Fig. S3B ). In contrast, dasatinib exerted broad anti-proliferative effects and significantly inhibited empty vector control cells in addition to PDGFRĮ expressing cells. Furthermore, concordant with the inability of dasatinib to block phosphorylation of the D842V mutant, cells expressing this mutant showed a diminished growth inhibitory response compared to other mutants ( Fig. 3B ). Crenolanib and dasatinib both exert cytostatic effects on PDGFRĮ-expressing p53-null PMAs, arresting cells in G0/G1 (Fig. S5 ). However, neither inhibitor induced significant cell death, as assessed by annexin V staining and TUNEL assays (data not shown). To determine if expression of wild-type PDGFRĮ or PDGFRĮ mutants renders p53-null PMAs tumorigenic, two million cells were implanted intracranially into the parietal lobe of two month old athymic nude mice and monitored daily for signs of morbidity. Mice were euthanized and brain tumor tissue was collected when mice became symptomatic.
PDGFRĮ mutations are oncogenic in vivo and drive development of HGGs
Brain tumors formed in 100% of mice implanted with cells expressing any of six different mutant forms of PDGFRĮ. Only one of 19 mice implanted with cells overexpressing wild-type PDGFRĮ developed a brain tumor, and none of the empty vector control cells developed into brain tumors in vivo. The tumor-induced morbidity was detected between 23 and 72 days for all mutants except E7del expressing tumors, which occurred at 103-119 days and the single tumor from wild-type PDGFRĮ, which occurred at 120 days post-implantation ( Fig.4A ). Standard histopathologic preparations from all tumors were evaluated (DWE) and classified according to WHO criteria ( Fig 4B and Table S3 ).
Overall, 63% (44/70) of tumors analyzed were grade III anaplastic astrocytoma, 26% (18/70) were grade III anaplastic oligoastrocytoma, 10% (7/70) were grade IV glioblastoma, and the single tumor that developed from cells expressing wild-type PDGFRĮ was the only low-grade tumor, a grade II oligoastrocytoma. Tumors expressing the D842V or V544ins mutation were significantly associated with anaplastic astrocytoma histology (p<0.0001 and p=0.0012 respectively) and tumors with E10del were significantly associated with anaplastic oligoastrocytoma histology (p=0.002). The rest of the evaluated tumors expressing C540ins, E10del2 and E7del mutations were not significantly associated with a specific morphology (p>0.2).
Immunohistochemical analysis for PDGFRĮ showed strong overexpression of the receptor throughout all tumors. PDGFRĮ-driven murine gliomas showed growth patterns Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on August 22, 2013; DOI: 10.1158/0008-5472.CAN-13-1491 similar to human high-grade gliomas including an easily visualized focal mass as well as diffuse infiltration into the normal brain parenchyma ( Fig.4C and Fig.S6A ). These tumors were immunopositive for p-4E-BP1 (Thr37/46) and p-Akt (Ser473) suggesting activated PDGFRĮ signaling (Fig.4C ). Furthermore, activation of PDGFRĮ in tumor tissues was confirmed by western blot analysis, which demonstrated high levels of phosphorylated receptor on Tyr-572/574, Tyr-742, Tyr-720, and Tyr-754 in all tumors examined but not in normal brain (Fig.4D) . Moreover, phosphorylation of PI3K pathway components, SHP2 and Src family kinases were strongly elevated compared to normal cortex. In contrast, levels of total STAT3 and phosphorylated STAT3 were similarly increased in all analyzed tumors compared to normal brain tissue, which may indicate cell-type specific differential expression of STAT3, not necessarily selective activation of STAT3 signaling in tumor. There was no significant difference in levels of MAPK pathway activation observed between tumor tissues and normal brain ( Fig.4D and   Fig.S6B ).
Gene expression signatures of PDGFRĮ-driven murine HGGs resemble human
HGGs
To evaluate the similarity of the molecular signatures of PDGFR-driven murine HGGs to human disease, gene expression profiles were analyzed for representative mutant and wild-type PDGFRĮ generated brain tumors. Additionally, gene expression profiles of EGFRvIII-driven murine HGGs were assayed for comparison (25) . Unsupervised hierarchical clustering (UHC) segregated the tumors into two distinct subgroups (Fig.   S7 ). Interestingly, PDGFRĮ and EGFRvIII expressing tumors were distributed among Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on August 22, 2013; DOI: 10.1158/0008-5472. CAN-13-1491 both subgroups, and there was no significant association of specific PDGFRĮ mutations or tumor histopathology with either of the identified subgroups. Furthermore, using single sample gene set enrichment analysis (GSEA) the gene expression profile of each murine tumor was compared to published signature gene sets for human HGG subgroups (proneural, proliferative and mesenchymal) and murine cell type-specific signatures (oligodendrocyte progenitor cells, oligodendrocytes, neurons, astrocytes and cultured astroglia) (30, 31) . We also compared the gene expression signatures of seven independent untransduced p53-null PMA cultures, which showed a significant similarity to the published expression signatures of astrocytes and cultured astroglia (31) .
Interestingly, transformation of p53-null PMAs by PDGFRα mutants resulted in gliomas
with a range of expression signatures representing the three major expression subgroups observed in human HGGs (Fig. 5) (30) . 37 .8% (14/37) of PDGFRĮ tumors showed proneural, 32.4% (12/37) proliferative and 16.2% (6/37) mesenchymal subgroup expression signatures. There was no significant association of specific PDGFRA mutations with a particular expression subgroup described in pediatric and adult HGGs (4, 5, 30) . Interestingly, tumors driven by E10del2 mutation were significantly associated with the oligodendrocyte progenitor cell gene expression signature (p=0.03), however there was no significant association between specific mutation and expression signature of cell types. 
Discussion
Aberrations of PDGFRĮ signaling via amplification and/or mutation of PDGFRA are frequent in pediatric HGGs. Here, targeted sequencing identified novel activating somatic mutations of PDGFRA in pediatric HGGs. Two recent studies reported PDGFRA mutations in pediatric HGGs, but the functional consequence on PDGFRĮ activation was not explored, and none of the described mutations overlapped with our findings (6, 12) . Interestingly, mutations were not represented by a single hotspot as observed in gastrointestinal stromal tumors. One of the identified mutations in this study, V544ins, a small duplication resulting in a 14 amino acid in-frame insertion, was found in the transmembrane domain, potentially facilitating oligomerization of the receptor via the transmembrane domain or disrupting the inhibitory conformation of the juxtamembrane region and consequently leading to ligand independent receptor dimerization and activation as observed for PDGFRȕ, c-Kit and other RTKs (43) (44) (45) .
In adult glioblastomas, the frequency of PDGFRA amplification and mutation is lower than in pediatric tumors and PDGFRA mutations comprise a distinct set of alterations compared to childhood disease (8, 9, 23, 34) . Approximately 40% of amplified PDGFRA in adult glioblastomas is not wild-type, but contains recurrent genomic deletions of Numerous mouse glioma models have been generated by expression of exogenous PDGF, driving paracrine stimulation of cells expressing endogenous PDGFR (17) (18) (19) (46) (47) (48) . In this study, gliomas were driven by the PDGFRA mutations found in pediatric HGGs. Both wild-type and mutant PDGFRĮ conferred a proliferative advantage to p53null PMAs in vitro, however, the wild-type showed minimal tumorigenic activity, resulting in only 1 of 19 mice developing a low-grade glioma while all six of the mutants induced high-grade glioma formation with 100% penetrance. In contrast, a previous study showed that wild-type PDGFRα transformed Ink4a/Arf-null PMAs to generate gliomas (49) . The difference in the gliomagenic activity of wild-type PDGFRα may be explained in part by a higher propensity for transformation in the recipient cells, as the Ink4a/Arfnull PMAs formed tumors at lower frequency in the absence of PDGFRα, while the early passage p53-null PMAs in the present study did not form any tumors. Additionally Ink4a/Arf and p53 loss may differentially cooperate with PDGFRα overexpression to drive glioma (49) . It is also possible that the levels of wild-type receptor expression in our model system were not sufficient to model the gene amplification that drives tumorigenesis in human tumors. However, the wild-type receptor was expressed at levels similar to the E7del, E10del and E10del2 mutations (Fig. 2) , which were also amplified in human tumors. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on August 22, 2013; DOI: 10.1158/0008-5472.CAN- The fact that all PDGFRĮ mutations showed ligand-independent phosphorylation while wild-type receptor activation required ligand stimulation, suggests lack of sufficient ligand in the brain of implanted adult animals, or different selective advantage conferred by wild-type PDGFRA amplification versus mutation with or without amplification.
Amplification of wild-type PDGFRA occurred more frequently in tumors within the brainstem (26%, 11/43 DIPG vs. 11%, 9/84 non-brainstem HGG, p=0.04), while PDGFRA sequence mutations were more common in pediatric HGG arising outside the brainstem, although this was not statistically significant (14%, 13/90 non-brainstem HGG vs. 5%, 2/43 DIPG, p=0.14) (4, 5) . Moreover, all six samples with concomitant amplification and mutation of PDGFRA were from non-brainstem tumors. Given the higher frequency of wild-type amplification in DIPGs, it is possible that wild-type PDGFRα requires a more specific or alternative cell of origin to drive transformation compared to the mutants, which may not be adequately recapitulated in our experimental system. These effects can vary among oncogenic mutations. For example EGFRvIII drives tumorigenesis equivalently from Ink4a/Arf-null cortical astrocytes or neural stem cells, while BRAF duplications show a differential growth response in cerebellar neural stem cells compared to astrocytes, and in neural stem cells from the cerebellum compared to those from neocortex (50, 51) . Furthermore, comparison of DIPG and non-brainstem pediatric HGG also revealed distinctive gene expression profiles, significant differences in the frequency of histone mutations and specific large-scale genomic imbalances, as well as the absence of focal deletion of CDKN2A in DIPG, which is common in pediatric non-brainstem HGG (4, 5, 11) . This suggests that distinct tumor microenvironments within different locations of the brain Research.
on October 30, 2017. © 2013 American Association for Cancer cancerres.aacrjournals.org Downloaded from may exert different selective pressures driving pediatric HGG, which could include differential susceptibility to PDGFRA mutation/amplification-driven tumorigenesis.
The tumors that arose from mutant PDGFRα-transformed PMAs showed a range of morphologies. Although the majority of murine HGGs were diagnosed as anaplastic astrocytomas or glioblastomas, a significant number of tumors showed a mixed glial (oligoastrocytic) phenotype. Because tumors were generated with virally-transduced astrocytes, this suggests that in a subset of tumors, signaling activated by mutated PDGFRĮ triggered astrocyte dedifferentiation as described for tumors induced by PDGFB ligand overexpression in cultured astrocytes (18). Alternatively, rare progenitor cell populations in the starting populations may give rise to some of the tumors. In several different studies, viral introduction of PDGF-B into brain induced gliomas with a predominantly proneural signature, perhaps driven in part by the endogenous cells that expressed PDGFR, and were therefore competent to respond to the exogenous ligand (18, 47, 52) . In contrast, the tumors arising from transduced PMAs in this study The consequence of oncogenic mutations to therapeutic inhibitors can have significant clinical ramifications. Some oncogenic mutations confer resistance to small molecule inhibitors. For example, PDGFRA D842V is a recurrent hotspot mutation in gastrointestinal stromal tumors that confers resistance to imatinib (32) . In contrast, some oncogenic mutations cause enhanced sensitivity to small molecule inhibitors and are associated with significantly prolonged survival, such as BRAF mutations in melanoma, or EGFR mutations in small cell lung cancer (53, 54) . This is highly dependent on the specific mutation rather than the therapeutic target, as illustrated by the different spectrum of EGFR mutations in adult glioblastomas that are not sensitive to the same small molecule inhibitors that work well in lung cancer (55) . All of the PDGFRα mutants tested here were inhibited by crenolanib, and most were inhibited by dasatinib. While it is promising that these mutations do not confer resistance to available small molecule PDGFR inhibitors, these compounds induced a cytostatic, but not cytotoxic response. This strongly suggests that clinical use of PDGFR inhibitors as a single agent may not be sufficient to cause regression of pediatric HGG, but could be a useful addition to other therapeutic approaches.
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Figure Legends
Author Manuscript Published OnlineFirst on August 22, 2013; DOI: 10.1158/0008-5472.CAN-13-1491 D) Western blot analysis of whole cell lysates from tissues of wild-type and mutant PDGFRĮ-driven brain tumors. Lysates from normal adult cortex (lanes N #1 and #2) were included as controls. Signaling pathway activation in PDGFRĮ-driven murine HGGs was assayed using the indicated antibodies.
Figure-5 Gene expression profiles of murine PDGFRĮ-driven HGGs resemble human
HGGs.
Heat map of single sample gene set enrichment analysis of representative murine brain tumors and untransduced p53-null PMA cultures using gene sets defining human HGG expression subgroups (PN-proneural, Pro-proliferative, Mes-mesenchymal) and murine cell type specific signatures (OPCs-oligodendrocyte progenitor cells, Oligooligodendrocyte, N-neurons, A-astrocytes and CA-cultured astroglia). The order of the tumor samples is arranged based on the unsupervised hierarchical clustering analysis using 1000 most variable probe sets, which reveled two major expression subgroups HC1 and HC2 ( Figure S7 ). The histology of each tumor is indicated above the heat map: anaplastic astrocytoma (purple), anaplastic oligoastrocytomas (green), glioblastoma (brown), oligoastrocytoma (yellow) and white mark tumors with no diagnosis available. Untransduced p53-null PMA cultures are marked with black.
